Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Rational Inhibitor Discovery for BRAFV600E Using PSeMut, a Sequence-Driven Model.

FASEB journal : official publication of the Federation of American Societies for Experimental Biology - 15 Jul 2026

Lu Bin, Wang Nan, Liu Jia, Zheng Juyan, Ge Minghua, Xu Tong, Huang Ping

Abstract excerpt

Mutational heterogeneity at drug targets both undermines small-molecule efficacy and contributes to disease. A practical response is to discover scaffolds that maintain potency in the presence of mutations; however, prevailing biological research strategies are not readily scalable, constraining high-throughput design and discovery. We present PSeMut, a structure-free Siamese model that contrasts wild-type and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Line, Tumor
Share to Drug Discovery

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to BRAF gene

Share to Mutation

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins B-raf

Source

Identifiers

PMID: 42406425
DOI: 10.1096/fj.202505042RR

Genes

BRAF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Rational Inhibitor Discovery for BRAFV600E Using PSeMut, a Sequence-Driven Model.PMID 42406425Read ↗

EvoSynth: Enabling Multi-Target Drug Discovery through Latent Evolutionary Optimization and Synthesis-Aware PrioritizationSemantic proximity Read ↗

ESMRank reveals a transferable axis of protein mutational constraint from overlapping variant effect assaysSemantic proximity Read ↗

Machine learning-guided drug repurposing for EGFR inhibition using scaffold-split validation, docking, and molecular dynamics.Semantic proximity Read ↗

Linobectide: a mathematical-chemistry modified black-hole algorithmic framework for ORF1p inhibitor designSemantic proximity Read ↗

Scaffold-Aware QSAR, BRICS Analog Design, and Docking Consensus for Prioritizing KRAS G12C-Targeted Cancer Therapeutic LeadsSemantic proximity Read ↗

Insights into the structure-activity relationship of pyrimidine-sulfonamide analogues for targeting BRAF V600E protein.Semantic proximity Read ↗

StabLyzeGraph: High-throughput screening of combinatorial mutations using graph neural networks.Semantic proximity Read ↗

Structure-based scaffold hopping reveals strategies to overcome oncogenic KIT and PDGFRA mutation-driven drug-resistance in GIST.Semantic proximity Read ↗

PROtein Analytics for Kinase Therapeutic Inhibitor Variants (PROAKTIV): A Machine learning approach to predict efficacy of tyrosine kinase inhibitors against mutations in EGFR, ALK and BRAFSemantic proximity Read ↗

From Latent Manifolds to Functional Probes: An Interpretable, Kinome-Scale Generative Machine Learning Framework for Family-Targeted Kinase Inhibitor DesignSemantic proximity Read ↗

Discovery of Selective Small-Molecule Ligands of SV2C by AI-Enhanced Virtual Screening and Experimental ValidationSemantic proximity Read ↗

Targeted design, synthesis, molecular simulation, ADME-T and in-vitro anticancer assessment of phenyl-substituted-thioxo-tetrahydro-pyrimidin-benzenesulfonamide derivatives as potential BRAFV600E/WT inhibitors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.